Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
Net Income
Iterum Therapeutics PLC
Net Income Peer Comparison
Competitive Net Income Analysis
Latest Figures & CAGR of Competitors
Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Net Income
-$35.6m
|
CAGR 3-Years
36%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Perrigo Company PLC
NYSE:PRGO
|
Net Income
-$7.7m
|
CAGR 3-Years
68%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Net Income
$414.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
18%
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Net Income
-$156.8m
|
CAGR 3-Years
-205%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Net Income
-$35.6m
|
CAGR 3-Years
-329%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Net Income
€7.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-20%
|
See Also
What is Iterum Therapeutics PLC's Net Income?
Net Income
-35.6m
USD
Based on the financial report for Mar 31, 2024, Iterum Therapeutics PLC's Net Income amounts to -35.6m USD.
What is Iterum Therapeutics PLC's Net Income growth rate?
Net Income CAGR 5Y
16%
Over the last year, the Net Income growth was 30%. The average annual Net Income growth rates for Iterum Therapeutics PLC have been 36% over the past three years , 16% over the past five years .